Physician profile
Robin L Elkus
NPI 1780630905
$2,603.36
in general payments reported to CMS, 2019-2025
17 companies · $450 in 2025
The $450 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $167 · 2021: $401 · 2022: $525 · 2023: $347 · 2024: $330 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838 · Consulting Fee: $200 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.60 |
| Consulting Fee | $200.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $793.37 | 2019-2023 | Breztri, Symbicort |
| Philips North America LLC | $374.92 | 2019-2025 | (8874) Incourage, (Ak6) Vest Therapy, Vest Therapy Und |
| Harmony Biosciences LLC | $307.28 | 2022-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $219.97 | 2025 | Lumryz |
| Sunovion Pharmaceuticals INC. | $166.02 | 2019 | |
| Glaxosmithkline, LLC. | $128.12 | 2021-2025 | Trelegy Ellipta, Nucala |
| Grifols USA, LLC | $119.72 | 2021-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.01 | 2020-2022 | |
| Axsome Therapeutics, INC. | $83.81 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $58.34 | 2019-2022 | |
| United Therapeutics Corporation | $54.06 | 2021-2022 | |
| Mylan Specialty L.P. | $46.41 | 2021-2022 | |
| Insmed, INC. | $45.71 | 2023-2025 | Arikayce |
| Inogen, INC. | $37.61 | 2023-2024 | Inogen |
| Verona Pharma, INC. | $30.82 | 2025 | Ohtuvayre |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.73 | 2024 | |
| Viatris Specialty LLC | $14.46 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Elkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.